University of Michigan portfolio
Company cancer-research description and university-reported launch year of 2021.
View the portfolio entryA clear route
to the source.
Public records and general background used to explain the company and research context. Source dates matter; a historical record is not a live status update.
Public context.
Explicit attribution.
These links are provided for readers who want to inspect the underlying records.
University drug pipeline
Page 3 lists DPI-503 under Dvant Pharma for cancer, in the preclinical column.
View the pipeline PDFRegents communication
Historical context for an EGFR technology license agreement involving Dvant. Current rights are subject to diligence.
View the Regents PDFDvant public company profile
The company’s stated EGFR-degrader focus and public leadership context.
View the company profileSEC Form D
Corporate identity and address information. The filing does not establish clinical efficacy or regulatory approval.
View the filing indexLearn the terminology.
These general educational resources do not validate a Dvant candidate or recommend a treatment.
What is EGFR?
A concise definition of the receptor and its role in cell signaling.
How drugs are developed
An overview of discovery, preclinical research, clinical research, review, and monitoring.